Profile: Fulgent Genetics Inc (FLGT.OQ)
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of September 02, 2016, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders.
The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers. The Company's advanced data comparison algorithms measure deoxyribonucleic acid (DNA) sequences from patient specimens against genetic data available from the scientific community and its reference library of genetic information, which enables to rapidly and effectively detect pathogenic mutations. The Company has developed software that automatically incorporates the data from each completed test into its genetic reference library. The Company offers laboratory information management systems.
The Company competes with Ambry Genetics, Inc., Counsyl Inc., Foundation Medicine, Inc., OPKO Health, Inc., Invitae Corporation, Myriad Genetics, Inc. and Pathway Genomics Corporation.
Fulgent Genetics Inc
4978 Santa Anita Ave Ste 205
TEMPLE CITY CA 91780-3600